Editorial draft — not for publication yet. Alprazolam content needs clinical and legal review before publication. This page is general information and is not advice about an individual prescription.

In short

Opsonin’s manufacturer insert identifies Alprax XR 1 mg as an extended-release tablet containing alprazolam, made in Bangladesh. The insert lists anxiety-related indications; this does not establish UK authorisation or make the product interchangeable with UK alprazolam tablets. Check the exact product with a UK pharmacist. Alprazolam can cause sedation, dangerous interactions, dependence and withdrawal.

For the general active-ingredient guide, continue to Alprazolam medicine guide. This page covers Alprax XR 1 mg-specific product questions.

Alprax XR 1 mg UK product status

Opsonin’s product insert identifies Alprax XR 1 mg as a Bangladesh-manufactured extended-release alprazolam tablet. A Bangladesh product leaflet or listing does not establish UK authorisation or supply for this exact brand, strength and presentation. UK product records for Xanax 250 and 500 microgram tablets concern distinct products and do not validate Alprax XR 1 mg. Check the exact pack in the current MHRA database or with a UK pharmacist. Alprazolam’s controlled-drug classification is separate from product authorisation.

What is Alprazolam used for in UK clinical care?

Opsonin’s manufacturer insert lists anxiety disorder, short-term excessive anxiety, panic disorder with or without agoraphobia, and anxiety associated with depression. These are product-information statements from a Bangladesh leaflet, not a UK treatment recommendation for Alprax XR. NICE limits benzodiazepine use for GAD and advises against benzodiazepines for panic disorder.

  • The Bangladesh manufacturer insert lists anxiety-related indications for Alprax/Alprax XR; confirm the indication on the leaflet for the exact product supplied.
  • The UK Xanax tablet product information covers short-term treatment of severe, disabling or extremely distressing anxiety in adults; it is not an Alprax XR authorisation.
  • NICE says benzodiazepines for generalised anxiety disorder should usually be limited to short-term crisis use and should not be prescribed for panic disorder.
  • Sedation or “hypnotic” properties do not make Alprax XR a general sleeping tablet or a self-treatment for insomnia.

A medicine leaflet’s indications, a product’s UK marketing authorisation and NICE clinical recommendations are separate things. Do not assume one confirms the others.

NICE recommends that any benzodiazepine reduction be planned with the person and generally proceed slowly in individualised steps. Do not stop regular alprazolam suddenly.

This is an editorial draft. A qualified UK clinician and regulatory reviewer must verify the product and all clinical claims before publication.

How does it work?

Alprazolam is a benzodiazepine that enhances inhibitory signalling involving GABA in the central nervous system. This can have a calming and sedating effect, but may also impair alertness, memory and coordination. The Alprax XR insert identifies an extended-release formulation; its release presentation is distinct from standard tablets.

Risks and possible effects

Sleepiness and impairment

Opsonin’s insert lists drowsiness and light-headedness, and describes confusion, unsteadiness, memory problems and muscle weakness. UK alprazolam product information also warns about sedation and impaired concentration or muscle function.

Get urgent help

Call 999 if someone is difficult to wake, collapses, becomes unresponsive or has slow or difficult breathing. The risk is especially serious when alprazolam is combined with opioids, alcohol or other sedatives.

Safety information

  • Verify the exact brand, strength, release type, manufacturer and UK product status; a Bangladesh leaflet does not establish UK authorisation.
  • Alprazolam can cause sedation, impaired coordination and memory effects. Do not drive or do hazardous tasks if impaired.
  • Alcohol and opioids can dangerously increase sedation and breathing risks. Ask a pharmacist to check all medicines and supplements.
  • Tolerance, dependence, addiction and withdrawal may occur. Agree a review and stopping plan with the prescriber, and do not stop regular use abruptly.
  • Discuss breathing or liver conditions, sleep apnoea, pregnancy, breastfeeding, mental-health history and prior substance-use problems with the clinician responsible for care.

What product is Alprax XR 1 mg?

Opsonin Pharma’s insert identifies Alprax XR 1 mg as an extended-release tablet containing alprazolam 1 mg and names Opsonin Pharma Limited in Bangladesh as the manufacturer. The “XR” is important: the insert distinguishes it from standard Alprax tablets.

Always verify the full product name, ingredient, strength, formulation and leaflet on the pack. A familiar brand name alone is not enough to identify a medicine safely.

Alprax XR and UK product status

The UK emc lists Xanax 250 microgram and 500 microgram tablets containing alprazolam. Those UK product records are for different tablets and do not establish authorisation or supply of Alprax XR 1 mg. Check the exact product in the MHRA database or with a pharmacist.

Alprazolam’s controlled-drug classification does not establish that a particular brand or imported pack is authorised. For travel, importation or legal questions, check current official guidance for the relevant UK nation.

Anxiety and sleep: do not treat product descriptions as UK advice

The Alprax manufacturer insert lists anxiety-related indications. NICE says benzodiazepines should generally be reserved for short-term crisis use for GAD and advises against them for panic disorder. UK Xanax product information is for short-term severe anxiety and is a distinct product record.

Alprazolam may cause sedation, but the exact Alprax XR insert does not list general insomnia as an indication. A sedative effect is not evidence that it is a suitable sleep treatment. Ask a clinician about persistent anxiety or sleep problems.

Interactions, dependence and urgent help

Alcohol, opioids and other sedating medicines can increase impairment; combining alprazolam with opioids can cause severe breathing suppression, coma or death. Give a pharmacist a complete medicines list before starting anything new.

Regular use can lead to tolerance, dependence and withdrawal. Do not stop suddenly; NICE recommends a gradual, individualised plan in most situations. Call 999 for severe breathing difficulty, collapse or inability to wake.

Frequently asked questions

What is Alprax XR 1 mg?

Opsonin identifies it as a Bangladesh-manufactured extended-release tablet containing alprazolam 1 mg.

Is Alprax XR 1 mg available on the NHS?

The Bangladesh manufacturer leaflet does not confirm UK authorisation or NHS supply. Check the exact product with a UK pharmacist and the MHRA database.

Can Alprax XR be used for sleep?

The exact manufacturer insert lists anxiety-related indications and does not identify Alprax XR as a general insomnia treatment. Do not use it for sleep unless your own prescriber has specifically instructed you.

Can I stop taking Alprax XR suddenly?

If you have taken alprazolam regularly, do not stop suddenly without medical advice. Ask your prescriber for an individualised plan.

Explore the detailed alprax xr 1 mg (alprazolam) guides

Each guide answers a different practical question. Advice is specific to alprazolam and should be checked against your own product leaflet and prescription.

Sources and review

This draft was checked against the sources below on 3 October 2026. It still requires clinical and legal review before publication.

Editorial status: Clinical and regulatory review required before publication.